Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cleveland BioLabs, Inc. (NASDAQ: CBLI).

Full DD Report for CBLI

You must become a subscriber to view this report.


Recent News from (NASDAQ: CBLI)

Cleveland Biolabs Reports Second Quarter 2018 Financial Results And Development Progress
BUFFALO, NY / ACCESSWIRE / August 14, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2018. Cleveland BioLabs reported a net loss of $(0.85) million, excluding minority interests, for the second qu...
Source: ACCESSWIRE
Date: August, 14 2018 17:15
Cleveland Biolabs Announces Formation and Financing of an Anti-Aging Joint Venture
Goal is to Develop and Commercialize Entolimod and Other Compounds for Anti-aging Applications BUFFALO, NY / ACCESSWIRE / August 14, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported formation of a 50-50 joint venture, named Genome Protection, Inc. (GPI), between the company ...
Source: ACCESSWIRE
Date: August, 14 2018 16:45
Midday Gainers / Losers (08/13/2018)
Gainers: ABIL +50% . IDRA +23% . TKAT +21% . CHRA +18% . XBIO +17% . DBD +18% . PTIE +13% . MTEX +13% . ITUS +12% . ATRS +11% . More news on: Ability Inc., Idera Pharmaceuticals, Inc., Takung Art Co., Ltd., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 13 2018 12:53
Cleveland BioLabs Announces Delay in Analysis of Biocomparability Data Required for Regulatory Submission
BUFFALO, NY / ACCESSWIRE / August 6, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported that the company has received vendor notification of delays in analytical analyses of a formulation biocomparability study required for the Company's regulatory submissions. These delays oblige ...
Source: ACCESSWIRE
Date: August, 06 2018 17:00
Wired News - Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1
Stock Monitor: Cleveland BioLabs Post Earnings Reporting LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want access to our free research report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ), all you need to do is sign up now by clicking the following link www.active-investors.com...
Source: ACCESSWIRE IA
Date: June, 12 2018 07:30
Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / May 15, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2018. Cleveland BioLabs reported a net loss of $(1.2) million, excluding minority interests, for the first quart...
Source: ACCESSWIRE
Date: May, 15 2018 08:00
Cleveland Biolabs Announces Progress on European Marketing Authorization Application
BUFFALO, NY / ACCESSWIRE / March 28, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported that the company has received Day 120 review questions from the European Medicines Agency (EMA) regarding the company's Marketing Authorization Application (MAA) for entolimod. The MAA seeks app...
Source: ACCESSWIRE
Date: March, 28 2018 17:05
Cleveland Biolabs Reports 2017 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / March 6, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2017. Cleveland BioLabs reported a net loss, excluding minority interests, of $(1.2) million for th...
Source: ACCESSWIRE
Date: March, 06 2018 08:00
Pluristem - Hidden Treasures And Sudden Catalysts
Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d...
Source: SeekingAlpha
Date: February, 08 2018 08:18
Cleveland Biolabs' Delay Supports Competitor Advantage In Acute Radiation Syndrome
Investment Thesis: Cleveland Biolabs ( CBLI ) is a microcap stock who has seen its share price collapse over the past 5 years due to concerns over their lead product Entomolid, primarily marketed as a radiation countermeasure. They have recently seen an uptick in their share price as they...
Source: SeekingAlpha
Date: January, 10 2018 18:14

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-171.71891.701.7551.703,241
2018-12-141.711.791.8711.714,379
2018-12-13N/A1.81N/AN/A195
2018-12-121.8091.891.951.801,876
2018-12-111.811.821.951.811,253

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-17101,8810.5316Cover
2018-12-145002,36121.1775Cover
2018-12-101,6602,97655.7796Short
2018-12-0724760440.8940Short
2018-12-061062,6603.9850Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBLI.


About Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Logo for Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Not available

 

Contact Information

 

 

Current Management

  • Yakov Kogan / CEO
  • Rachael Llevine / IR

Current Share Structure

  • Market Cap: $31,696,334 - 05/14/2018
  • Issue and Outstanding: 11,279,834 - 05/05/2017

 


Recent Filings from (NASDAQ: CBLI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: March, 21 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 28 2018

 

 


Daily Technical Chart for (NASDAQ: CBLI)

Daily Technical Chart for (NASDAQ: CBLI)


Stay tuned for daily updates and more on (NASDAQ: CBLI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CBLI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBLI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CBLI and does not buy, sell, or trade any shares of CBLI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/